Literature DB >> 836826

Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes.

L D Steger, R J Desnick.   

Abstract

Entrapment of enzyme in liposomes, biodegradable lipid vesicles, offers an intriguing strategy for the intracellular delivery of these macromolecules to the lysosomal apparatus for enzyme replacement endeavors in selected lysosomal storage diseases. Therefore, the in vivo tissue and subcellular fate and effect on the subcellular distribution of endogenous lysosomal hydrolases was determined following intravenous administration of beta-glucuronidase entrapped in positively and negatively charged liposomes into C3H/HeJ beta-glucuronidase-deficient mice. Enzyme entrapped in negatively charged liposomes was rapidly cleared from the circulation (t1/2 approximately 4 min); maximal tissue recovery, 75% of dose, was detedtec in the liver at 1 h, was maintained fro 48 h and then gradually declined to non-detectable levels by 8 days. A similar circulatory clearance and reciprocal hepatic uptake was observed fro positively charged liposomes; however, the beta-glucuronidase was retained in murine liver for 11 days. Significant activity, 15% of dose, was found in the kidneys up to 1 and 4 days post-injection of positively and negatively charged liposomes, respectively. No activity was recovered in neural or other visceral tissues except in spleen and lungs (less than 5% of the dose). Exogenous beta-glucuronidase activity administered in negatively charged liposomes was primarily localized in the lysosomally-enriched hepatic subcellular fraction, compared to the predominantly soluble localization of exogenous activity entrapped in positively charged liposomes. Administration of negatively charged liposomes caused no detectable change in the subcellular localization of several endogenous lysosomal hydrolase activities compared to their distribution in untreated mice. In contrast, a marked but temporary translocation of these hydrolase activities into the soluble fraction was observed following the administration of positively charged liposomes, identifying possible deleterious effects on cellular physiology.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 836826     DOI: 10.1016/0005-2736(77)90028-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

Review 1.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

2.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

3.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

Review 4.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

5.  Pharmacological effects of phosphatidylserine liposomes: regulation of gylcolysis and energy level in brain.

Authors:  E Bigon; E Boarato; A Bruni; A Leon; G Toffano
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

6.  Beta-glucuronidase deficiency: enzyme studies in an affected family and prenatal diagnosis.

Authors:  I Maire; G Mandon; M T Zabot; M Mathieu; P Guibaud
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

7.  Association of liposomes with the isolated perfused rabbit heart.

Authors:  S Kayawake; K J Kako
Journal:  Basic Res Cardiol       Date:  1982 Nov-Dec       Impact factor: 17.165

8.  Control of in vitro cytotoxicity of positively charged liposomes.

Authors:  E A Panzner; V K Jansons
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

9.  Pharmacological effects of phosphatidylserine liposomes: the role of lysophosphatidylserine.

Authors:  E Bigon; E Boarato; A Bruni; A Leon; G Toffano
Journal:  Br J Pharmacol       Date:  1979-12       Impact factor: 8.739

10.  Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Authors:  Ritesh Thekkedath; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2012-12-02       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.